Clinical trials: Solid Cancer
Liver Cancer, Rhabdomyosarcoma
Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
Patients may be considered if the cancer has come back, has not gone away after standard treatment or the patient cannot receive standard treatment.
- Conditions
- Liver Cancer, Rhabdomyosarcoma, Malignant Rhabdoid Tumor, Liposarcoma
- Trial name
- NCT04377932
- Testing
- AGAR T cells
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Baylor College of Medicine
Advanced Solid Tumor, CNS Tumor
Study With Infigratinib in Subjects With Advanced Solid and CNS Tumors or Recurrent or Progressive Low-Grade Glioma With Selected FGFR1-3 Alterations
The phase 1b study is aimed at determining the pediatric recommended phase 2 dose (RP2D) of Infigratinib. The phase 2 study will evaluate efficacy and safety of infigratinib.
- Conditions
- Advanced Solid Tumor, CNS Tumor, Recurrent WHO Grade II Glioma
- Trial name
- NEWEL (NCT05222165)
- Testing
- Infigratinib
- Where
- 10 sites in United States, Canada and 1 more
- Sponsor
- Helsinn Healthcare SA
Solid Tumor, Childhood, Lymphoma
Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer
Arm 1 of this research study is studying an investigational drug called BMS-986158 as a possible treatment for pediatric solid tumors or lymphoma.
- Conditions
- Solid Tumor, Childhood, Lymphoma, Brain Tumor, Pediatric
- Trial name
- NCT03936465
- Testing
- BMS-986158, BMS-986378
- Where
- 6 sites in United States, Canada
- Volunteers
- 41 people
- Sponsor
- Dana-Farber Cancer Institute
Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Effect of Bevacizumab and VEGF on Platelet Clustering in Patients Who Are Receiving Bevacizumab for Cancer
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about the effect of bevacizumab and VEGF on platelet clustering.
- Trial name
- NCT00898794
- Testing
- bevacizumab, coagulation study, laboratory biomarker analysis
- Where
- Switzerland
- Volunteers
- 20 people
- Sponsor
- Kantonsspital Graubünden
Abdominal Neoplasms
22 Gauge Needle for EUS Guided Tissue Acquisition of Samples for Histologic Examination
To determine the yield of tissue biopsy specimen and the diagnostic accuracy of tissue acquisition using a newly developed 22 gauge needle in patients with solid lesions throughout the GI tract.
- Trial name
- EUSFNTA (NCT04032951)
- Testing
- Fine Needle Tissue Acquisition
- Where
- 2 sites in Italy
- Volunteers
- 100 people
- Sponsor
- Catholic University of the Sacred Heart
Vaccination, Hematologic Malignancy
Vaccination for Children of H&O and Their Parents
The purpose of this study is to study on compliance, safety and effectivity of vaccination for children with hematologic malignancies or solid tumors and their parents.
- Conditions
- Vaccination, Hematologic Malignancy, Solid Tumor, Childhood
- Trial name
- NCT03373656
- Testing
- Vaccination, No Vaccination
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Children's Cancer Group, China
Advanced Cancers, Solid Tumors
Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients
The goal of this clinical research study is to find the highest tolerable dose of the combination of Votrient (pazopanib) and Afinitor (everolimus) that can be given to patients with advanced cancer.
- Trial name
- NCT01430572
- Testing
- Pazopanib, Everolimus
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- M.D. Anderson Cancer Center
Cancer, Solid Cancer
Immune Modulation With PRaG-1 Treatment
The study is a single-center, prospective, single-arm, Phase II clinical trial. Eligible patients with advanced solid malignant tumors will sign the informed consent form and undergo screening for enrollment.
- Trial name
- NCT07002502
- Testing
- PRaG-1(cordycepin tablet)
- Volunteers
- 19 people
- Sponsor
- Second Affiliated Hospital of Soochow University
Pancreatic Cyst, Pancreatic Neuroendocrine Carcinoma
Diagnosis of PCL With EUS-FNA and Cross-sectional Imaging - A Report of Accuracy
Pancreatic cystic lesions (PCLs) comprise of a heterogeneous group of entities that are benign, premalignant or malignant. With increased use of modern imaging techniques in recent years, incidentally discovered PCL have become…
- Conditions
- Pancreatic Cyst, Pancreatic Neuroendocrine Carcinoma, Pancreatic Pseudocyst, Pancreatic Serous Cystadenoma
- Trial name
- NCT03884179
- Volunteers
- 58 people
- Sponsor
- Sahlgrenska University Hospital
Haematological Malignancy, Solid Tumour
DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol
DETERMINE is an open-label phase II/III trial. It will look at targeted treatments in rare cancers or common cancers with rare genetic change (mutation). Patients must have a cancer with an identified mutation.
- Trial name
- DETERMINE (NCT05722886)
- Testing
- Alectinib, Atezolizumab, Entrectinib
- Where
- 27 sites in United Kingdom
- Volunteers
- 825 people
- Sponsor
- Cancer Research UK
Bone Cancer, Bone Tumor
A Dose Finding Study to Treat Bone Tumor(s)
To determine the Maximum Tolerated Dose (MTD) of CycloSam®, Samarium-153-DOTMP (Sm-153-DOTMP), a radiopharmaceutical that delivers radiation to the bone when injected, given as a tandemly administered pair of doses to subjects…
- Conditions
- Bone Cancer, Bone Tumor, Solid Tumor, Metastatic Cancer to the Bone
- Trial name
- NCT06008483
- Testing
- 153-Sm-DOTMP (Samarium-153-DOTMP)
- Where
- 4 sites in United States
- Volunteers
- 5 people
- Sponsor
- QSAM Therapeutics, Inc.
Neuroblastoma, Brain Tumors
Studies of Temozolomide in Combination With Topotecan in Refractory and Relapsed Paediatric Solid Tumours
The purpose of the study is to determine whether the combination of Hycamtin (Topotecan) and Temozolomide is effective in the treatment of relapsed and refractory neuroblastoma and other paediatric solid tumors.
- Conditions
- Neuroblastoma, Brain Tumors, Solid Tumors
- Trial name
- TOTEM2 (NCT00918320)
- Testing
- Temozolomide/Hycamtin (Topotecan)
- Where
- France
- Volunteers
- 129 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Solid Tumors, Primary Brain Tumors
Metformin in Children With Relapsed or Refractory Solid Tumors
The purpose of this study is to evaluate the tolerability and safety of escalating doses of metformin on a backbone of vincristine, irinotecan and temozolomide (VIT) in children with recurrent and refractory solid tumors.
- Trial name
- NCT01528046
- Testing
- Vincristine, Irinotecan, Temozolomide
- Where
- 14 sites in United States
- Volunteers
- 26 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Unspecified Childhood Solid Tumor, Protocol Specific
Viral Therapy in Treating Young Patients With Relapsed or Refractory Solid Tumors
This phase I trial studies the side effects and the best dose of viral therapy in treating young patients with solid tumors that have come back or that have not responded to standard therapy.
- Trial name
- NCT01240538
- Testing
- wild-type reovirus, cyclophosphamide, laboratory biomarker analysis
- Where
- 27 sites in United States, Canada
- Volunteers
- 26 people
- Sponsor
- National Cancer Institute (NCI)
Wilms Tumor, Neuroblastoma
Pharmacokinetic Study of Doxorubicin in Children With Cancer
Analyze pharmacokinetics of doxorubicin in children with cancer. Furthermore investigate the predictive role of troponin and natriuretic peptides for anthracycline-induced cardiotoxicity .
- Conditions
- Wilms Tumor, Neuroblastoma, Soft Tissue Sarcoma, Acute Lymphoblastic Leukemia
- Trial name
- Doxo (NCT01095926)
- Testing
- doxorubicin
- Where
- 23 sites in France, Germany and 2 more
- Volunteers
- 101 people
- Sponsor
- University Hospital Muenster
Non Small Cell Lung Carcinoma, Renal Cell Carcinoma
Retifanlimab and Ruxolitinib In Solid Malignancies
The goal of this clinical trial is to learn what dose of ruxolitinib can be given safely together with retifanlimab in patients with metastatic renal cell carcinoma and non-small cell lung carcinoma.
- Trial name
- PRISM (NCT07219576)
- Testing
- Ruxolitinib, Retifanlimab
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of California, San Diego
Lymphoma, Brain Neoplasms
RO4929097 in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia
Background: The anti-cancer drug RO4929097 is being tested for its ability to block blood vessel growth to tumors and slow or stop the growth of cancer cells.
- Conditions
- Lymphoma, Brain Neoplasms, Sarcoma, Osteosarcoma
- Trial name
- NCT01236586
- Testing
- RO4929097, Dexamethasone
- Where
- 2 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Stage IV Melanoma, Stage IV Renal Cell Cancer
flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer
RATIONALE: The drug flt3L may stimulate a person's immune system and help to kill tumor cells. Vaccines made from melanoma cells may make the body build an immune response to and kill their tumor cells.
- Conditions
- Stage IV Melanoma, Stage IV Renal Cell Cancer, Recurrent Renal Cell Cancer, Recurrent Melanoma
- Trial name
- NCT00019396
- Testing
- flt3 ligand, gp100 antigen, MART-1 antigen
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Solid Neoplasms With NTRK Fusions
Retrospective Analysis of the Experience With Larotrectinib in Patients With Solid Neoplasms With NTRK Fusion in Spain (SPAINTRK)
SPAINTRK aims to be the first trial in Spain to systematically collect data on outcomes of Spanish patients with solid neoplasms treated with Larotrectinib through the compassionate drug use program, during the time elapsed…
- Trial name
- SPAINTRK (NCT06837090)
- Where
- 14 sites in Spain
- Volunteers
- 20 people
- Sponsor
- Grupo Espanol de Tumores Neuroendocrinos
Recurrent Neuroblastoma, Unspecified Childhood Solid Tumor, Protocol Specific
Decitabine, Doxorubicin, and Cyclophosphamide in Treating Children With Relapsed or Refractory Solid Tumors or Neuroblastoma
This phase I trial is studying the side effects and best dose of decitabine when given together with doxorubicin and cyclophosphamide in treating children with relapsed or refractory solid tumors or neuroblastoma.
- Trial name
- NCT00075634
- Testing
- decitabine, doxorubicin hydrochloride, cyclophosphamide
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)